Association of ST6GAL1 and CYP19A1 polymorphisms in the 3′-UTR with astrocytoma risk and prognosis in a Chinese Han population

Table 4 Multivariate analysis of prognostic factors for survival rate in astrocytoma patients

Variable		No. of patients/events	OS		PFS
Variable		No. of patients/events	HR (95% CI)	p	HR (95% CI)	p
Surgical method	STR	3/3	1.00		1.00
	GTR	248/213	0.03 (0.01–0.09)	< 0.001	0.01 (0.00–0.02)	< 0.001
	NTR	114/112	0.03 (0.01–0.13)	< 0.001	0.01 (0.00–0.03)	< 0.001
Chemotherapy	NO	219/205	1.00		1.00
	Platinum-based	75/70	0.78 (0.59–1.03)	0.075	0.92 (0.69–1.22)	0.544
	ACNU	41/36	0.74 (0.51–1.06)	0.099	0.93 (0.65–1.34)	0.691
	TMZ	30/17	0.29 (0.17–0.50)	< 0.001	0.40 (0.23–0.69)	0.395
ST6GAL1 rs2239611	GG	244/219	1.00		1.00
	AG	107/95	1.01 (0.79–1.29)	0.947	0.99 (0.76–1.29)	0.945
	AA	14/14	1.92 (1.11–3.34)	0.020	1.64 (0.93–2.90)	0.088

Bold values indicate a significant difference (p < 0.05)
OS Overall survival, PFS Progression-free survival, GTR Gross total resection, NTR Near-total resection, STR Sub-total resection, HR Hazard ratio, ACNU Nimustine, TMZ Temozolomide

ISSN: 1471-2407